Introduction {#sec1}
============

Sleep is an important physiologic process, and sleep disturbances have been shown to negatively influence many aspects of quality of life, including general health, physical functions, cognitive functions, daily activities, and work performance \[[@cit0001]\]. Previous studies have determined that impaired sleep quality is common in hypertensive patients and may be associated with lower health-related quality of life \[[@cit0002], [@cit0003]\]. Moreover, poor sleep quality has been significantly associated with resistance to treatment in hypertensive patients \[[@cit0002]\].

Masked hypertension (MHT) is clinically defined as normal blood pressure (BP) levels during clinic monitoring with an average systolic BP ≥ 135 mm Hg and diastolic BP ≥ 85 mm Hg following 24 h of ambulatory monitoring \[[@cit0004]\]. The clinical importance of MHT has been underscored recently by reports of higher cardiovascular mortality and morbidity, as well as higher prevalence of target organ damage, in patients with MHT than in patients with normal clinic and ambulatory BP readings \[[@cit0005], [@cit0006]\]. Moreover, obstructive sleep apnea syndrome has been independently associated with an increased rate of MHT \[[@cit0007], [@cit0008]\]. Diagnosing MHT can be difficult in the outpatient clinics, and the diagnostic period for a first appointment with an outpatient clinic can be long. The detailed history, physical examination, and electrocardiograph are of limited value in the diagnosis of MHT. However, sleep quality in patients with MHT has not yet been reported in the literature.

We hypothesized that there is a relationship between MHT and impaired sleep quality. Thus, in this study, we evaluated the diagnostic role and prevalence of poor sleep quality among patients with newly diagnosed masked hypertension.

Material and methods {#sec2}
====================

Subjects and study protocol {#sec2.1}
---------------------------

We selected 72 newly diagnosed MHT patients and 40 normotensive healthy volunteers well balanced for gender, age, and body mass index (BMI). All patients underwent evaluation comprising 12-lead electrocardiography (ECG), transthoracic echocardiography, 24-hour Holter ECG, and basic laboratory tests. Height and weight were measured for calculation of the BMI (BMI = weight (kg)/height^2^ (m^2^)). The inclusion criteria for the study group were: age ≥ 18 years, patient's informed consent granted, absence of any acute disease, no administration of B-group vitamins or vitamin preparations within 6 months before the study and normotensive in physical treatment. Patients with any of the following features were excluded from participation: night-time workers, patients with valvular heart disease or chronic obstructive pulmonary disease (identified by a chest physician), patients with a history of sleep apnea/hypopnea, patients with recent acute coronary syndrome (within the last 2 months), significant systemic disease, history of any psychiatric disease including primary insomnia, symptomatic cerebrovascular disease (including previous transient ischemic attack within 6 months), obstructive coronary artery disease, history of congestive heart failure, hepatic failure, hypertension above study criteria as well as suspicion of secondary hypertension forms, with serum creatinine \> 1.4 mg/dl, patients with a history of diabetes mellitus (or fasting blood glucose \> 125 mg/dl), pregnant women, patients with hypo-hyperthyroidism, patients with a BMI \> 25 kg/m^2^, and patients who wished to consume alcohol during the study period. Patients using medications which are known for their negative impact on sleep quality, diuretics, β blocking agents which disturb sleep quality because of increased urine output, major psychotropic agents, oral steroids, daily nonsteroidal anti-inflammatory drugs, or high-dose acetylsalicylic acid were not included in the study.

Office blood pressure measurement {#sec2.2}
---------------------------------

Clinical systolic and diastolic BP recordings were performed according to the standard technique using a mercury sphygmomanometer. Blood pressure was measured in the sitting position on the right arm. Measurements were repeated three times, and the average value was used as the BP.

Ambulatory blood pressure monitoring {#sec2.3}
------------------------------------

Twenty-four-hour BP was measured by the cuff-oscillometric method using the ambulatory BP monitor Scanlight III version B (Medset Electronics, Hamburg, Germany). Blood pressure was measured every 30 min from 6 a.m. to midnight and every 60 min from midnight to 6 a.m. the following day. Daytime and nighttime BPs were obtained as the average values in the awake period between 6 a.m. and midnight and in the sleeping period between midnight and 6 a.m. The average 24-hour systolic and diastolic BPs were evaluated. All subjects were divided into two groups, dipper and non-dipper, according to the percentage of reduction in their nighttime BPs. Subjects were defined as dippers when nighttime systolic and diastolic BPs decreased ≥ 10% and as non-dippers when nighttime BP decreased \< 10%. Within patients having \< 140/90 mm Hg office BP, those having ≥ 135/85 average BP values in the day period of 24-hour ambulatory BP monitoring records were evaluated as masked hypertensive.

Echocardiography {#sec2.4}
----------------

An experienced echocardiographer performed the echocardiographic studies to exclude structural heart disease. All patients were evaluated by transthoracic M-mode and two-dimensional pulsed wave, continuous wave, color flow, and tissue Doppler imaging modalities. All examinations were performed with the GE-Vivid-3 system (GE Vingmed, Horten, Norway) with a 2--4 MHz transducer at a depth of 16 cm. Two-dimensional Doppler echocardiographic examinations and M-mode measurements were taken according to the recommendations of the American Society of Echocardiography \[[@cit0009]\].

Measurement of sleep quality {#sec2.5}
----------------------------

The Pittsburgh Sleep Quality Index (PSQI) is a standardized questionnaire to retrospectively document subjective sleep quality during the past 4 weeks \[[@cit0010]\]. This instrument is composed of 10 questions, distributed in seven components, as follows: Sleep duration, Subject sleep quality, Sleep latency, Habitual sleep efficiency, Sleep disorders, Use of medication to sleep, and Daytime somnolence and disorders. Each category can score up to three points. The instrument total score varies from 0 to 21 points; the higher the score is, the lower is the sleep quality. A score \> 5 points indicates low sleep quality.

Statistical analysis {#sec2.6}
--------------------

Descriptive statistics were performed and all data were expressed as mean ± SD and percentage ratio. The normality of data was tested using the Kolmogorov-Smirnov test. Parameter differences between the 2 groups were evaluated using the one-way ANOVA test for normally distributed variables and the Kruskal-Wallis test for non-normally distributed variables. For post hoc analysis of normally distributed variables Tukey's b test was used. For post hoc analysis of non-normally distributed variable origin, the Bonferroni-corrected Mann-Whitney U-test was used. For comparison of categorical variables, the χ^2^ test or Fisher's exact test was used as appropriate. Pearson's and Spearman's correlation coefficients were used to test the relationship between the systolic/diastolic arterial tension and PSQI scores. Multivariate logistic regression was conducted to identify statistically significant variables associated with PSQI scores. The results were considered significant when *p* was less than 0.05. We used the software package SPSS 20.0 (SPSS Inc., Chicago, IL, USA) for statistical analysis.

Results {#sec3}
=======

Initially 230 patients were included. One hundred twelve patients met the inclusion criteria and 118 patients were excluded. A total of 112 individuals were included in the present study. Recruitment, exclusion, and subsequent grouping of all patients are shown in the flowchart ([Figure 1](#f0001){ref-type="fig"}). Two groups of patients were compared: the MHT group (*n* = 72) and the control group (*n* = 40; normotensive healthy volunteers). Both groups were diagnosed during the study period using 24-hour ambulatory BP measurement.

![Recruitment, exclusion, and subsequent grouping of all patients](AMS-12-25052-g001){#f0001}

Baseline clinical and demographic characteristics of the patients were similar in both groups ([Table I](#t0001){ref-type="table"}). Comparison of clinical variables between groups showed that only systolic blood pressure, diastolic BP and dipper/non-dipper value levels were significantly different between groups (*p* \< 0.05). The non-dipper pattern was found in 17.5% of the healthy volunteer group and in 59.94% (*n* = 41) of the MHT group (*p* \< 0.001).

###### 

Comparative demographic, clinical, and laboratory parameters in the 2 groups of patients

  Parameter                                        MHT (*n* = 72)   Control (*n* = 40)   *P*-value
  ------------------------------------------------ ---------------- -------------------- ----------------------------------------------
  Age \[years\][\*](#tf1-1){ref-type="table-fn"}   47.4 ±11.3       46.1 ±10.2           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Gender (male/female)\], *N*                      42/30            26/14                \> 0.05[\*\*\*](#tf1-3){ref-type="table-fn"}
  Body mass index \[kg/m^2^\]                      26.2 ±2.3        25.7 ±2.5            \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Waist circumference \[cm\]                       87.2 ±2.9        86.9 ±2.6            \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Smoker/non-smoker, *N*                           32/40            14/26                \> 0.05[\*\*\*](#tf1-3){ref-type="table-fn"}
  SBP \[24 h\][\*](#tf1-1){ref-type="table-fn"}    151.2 ±23.1      129.1 ±11.2          \< 0.001[\*\*](#tf1-2){ref-type="table-fn"}
  DBP \[24 h\][\*](#tf1-1){ref-type="table-fn"}    96.4 ±12.2       81.2 ±5.6            \< 0.001[\*\*](#tf1-2){ref-type="table-fn"}
  Dipper vs. non-dipper, *N*                       31/41            33/7                 0.0013[\*\*\*](#tf1-3){ref-type="table-fn"}
  Metabolic syndrome (present/absent), *N*         23/49            11/29                \> 0.05[\*\*\*](#tf1-3){ref-type="table-fn"}
  Fasting blood glucose \[mmol/l\]                 5.11 ±0.51       5.01 ±0.43           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Blood urea nitrogen \[mmol/l\]                   5.31 ±0.54       5.06 ±0.41           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Creatinine \[μmol/l\]                            79.3 ±29.2       75.3 ±18.2           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Hemoglobin \[g/l\]                               143.7 ±42.3      140.5 ±34.3          \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Sodium \[mmol/l\]                                141.5 ±8.21      140.9 ±8.33          \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Potassium \[mmol/l\]                             4.33 ±0.35       4.29 ±0.23           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Calcium \[mmol/l\]                               2.33 ±0.11       2.41 ±0.11           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Phosphorus \[mmol/l\]                            1.13 ±0.14       1.09 ±0.12           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Total cholesterol \[mmol/l\]                     5.33 ±1.16       5.21 ±1.01           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  LDL cholesterol \[mmol/l\]                       3.19 ±0.88       3.06 ±0.81           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  HDL cholesterol \[mmol/l\]                       1.31 ±0.36       1.30 ±0.29           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}
  Triglyceride \[mmol/l\]                          1.58 ±0.72       1.49 ±0.65           \> 0.05[\*\*](#tf1-2){ref-type="table-fn"}

SBP -- systolic blood pressure, DBP -- diastolic blood pressure, LDL -- low-density lipoprotein, HDL -- high-density lipoprotein.

Mean ± standard deviation

p-value is based on one-way ANOVA test

p-value is based on chi-square test or Fisher's exact test as appropriate.

The comparison of echocardiographic parameters: left ventricular hypertrophy (LVH), including interventricular septum thickness (IVST), ejection fraction (EF), E/A ratio, and presence of left ventricular diastolic dysfunction (LVDD); IVST, the presence of LVH and LV posterior wall thickness, right wall thickness, LV mass, and LV mass index were significantly higher, and E/A ratio was significantly lower in the MHT group (*p* \< 0.001 for all comparisons). The total comparison of electrocardiographic and echocardiography findings between the groups is presented in [Table II](#t0002){ref-type="table"}.

###### 

Comparison of electrocardiographic and echocardiographic findings between groups

  Parameter                                              MHT (*n* = 72)   Control (*n* = 40)   *P*-value
  ------------------------------------------------------ ---------------- -------------------- -----------------------------------------------
  LVH (based on ECG), present/absent, *N*                34/38            3/37                 \< 0.001[\*\*\*](#tf2-3){ref-type="table-fn"}
  IVST \[mm\][\*](#tf2-1){ref-type="table-fn"}           1.23 ±0.12       0.92 ±0.14           \< 0.001[\*\*](#tf2-2){ref-type="table-fn"}
  PWT \[mm\][\*](#tf2-1){ref-type="table-fn"}            1.17 ±0.10       0.90 ±0.11           \< 0.001[\*\*](#tf2-2){ref-type="table-fn"}
  RWT \[mm\][\*](#tf2-1){ref-type="table-fn"}            0.43 ±0.06       0.39 ±0.6            \> 0.05[\*\*](#tf2-2){ref-type="table-fn"}
  LV mass \[g\]                                          193.23 ±12.21    165.42 ±10.42        \< 0.001[\*\*](#tf2-2){ref-type="table-fn"}
  LV mass index[\*\*\*\*](#tf2-4){ref-type="table-fn"}   103.57 ±7.24     86.73 ±8.75          \< 0.001[\*\*](#tf2-2){ref-type="table-fn"}
  EF (%)                                                 59.11 ±9.21      61.21 ±11.24         \> 0.05[\*\*](#tf2-2){ref-type="table-fn"}
  LVDD, present/absent, *N*                              25/47            5/35                 \< 0.001[\*\*\*](#tf2-3){ref-type="table-fn"}
  E/A ratio                                              0.91 ±0.15       1.21 ±1.02           \< 0.001[\*\*](#tf2-2){ref-type="table-fn"}

LVH -- left ventricular hypertrophy, IVST -- interventricular septum, EF -- ejection fraction, LVDD -- left ventricle diastolic dysfunction, PWT -- posterior wall thickness, RWT -- right ventricular wall thickness.

Mean ± standard deviation

p-value is based on one-way ANOVA test

p-value is based on chi-square test or Fisher's exact test as appropriate.

LVH defined as LV mass index of \> 116.0 in men and \> 104.0 in women.

The PSQI total score was significantly higher in the MHT group than in normotensive healthy volunteers (4.13 ±2.43 vs. 2.33 ±1.67, *p* \< 0.001, [Figure 2](#f0002){ref-type="fig"}). Poor sleep quality (PSQI \> 5) was found in 45.8% (*n* = 33) of the MHT group and 15% (*n* = 6) of the healthy group (*p* \< 0.001). When we compare MHT groups by dipping pattern, there was a significant difference in PSQI score between dipper and non-dipper groups (4.87 ±3.21 vs. 3.58 ±2.33, *p* \< 0.001). In addition, there was a significant positive correlation between PSQI score and systolic TA values (*r* = 0.563, *p* \< 0.001).

![Distribution of PSQI scores in MHT group and normotensive healthy subjects](AMS-12-25052-g002){#f0002}

Multiple logistic regression analyses showed that MHT (odds ratio (OR) = 6.79; 95% confidence interval (CI): 1.24--21.3; *p* \< 0.001), LV mass (OR = 2.53; 95% CI: 1.46--6.72; *p* \< 0.001), and LV mass index score (OR = 2.19; 95% CI: 1.42--5.76; *p* \< 0.001) were factors that could independently predict poor PSQI (PSQI score \> 5 points indicates low sleep quality).

Discussion {#sec4}
==========

This is the first study to evaluate sleep quality using Pittsburgh Sleep Quality Index (PSQI) scores in newly diagnosed MHT patients. Our results indicate significantly greater impairment of sleep quality scores among MHT patients than normotensive subjects. In addition, a non-dipper pattern was significantly more common in MHT patients than in normotensive subjects, and it was correlated with higher PSQI scores. Thus, sleep quality was significantly disturbed in non-dipper MHT patients, and the frequency of poor sleep quality, defined as a PSQI score \> 5, was greater in MHT patients, particularly those in the non-dipper group. Additionally, this study indicates that impaired sleep quality may help diagnose MHT, particularly in the non-dipper group.

The importance of MHT was recognized a decade ago in a study by Pickering *et al.* \[[@cit0011]\] that introduced the term MHT to describe individuals with normal clinic BP levels (\< 140/90 mm Hg) and ambulatory hypertension (awake ≥ 135/85 mm Hg). Previous studies showed a clear association between MHT and an increased risk of cardiovascular disease events with increased cardiovascular end-organ damage \[[@cit0012]--[@cit0014]\]. A meta-analysis of observational studies by Trevisol *et al.* \[[@cit0015]\] showed that quality of life and sleep quality in hypertensive patients were worse than in normotensive individuals. Taken together, these results revealed that hypertension and impaired sleep quality are common and may be associated with lower health-related quality of life. Interestingly, an analysis by Palagini *et al.* \[[@cit0016]\] showed that impaired sleep quality, short sleep duration, and persistent insomnia were associated with increased BP and increased risk of hypertension, even after controlling for other risk factors. They indicated that alterations in sleep quality might act as a neurobiological and physiologic stressor resulting in increased arterial pressure and hypertension.

This is the first study to examine sleep quality in patients with MHT. We determined that sleep quality was impaired in patients with MHT, which may disrupt appetitive hormone regulation and play a role in the pathogenesis of MHT. Poor sleep quality may be an important factor to consider in the diagnosis and treatment of MHT because evaluating sleeping status and sleep quality may help unmask MHT, enabling physicians to diagnose and appropriately treat MHT more effectively. Additional studies are needed to confirm the high prevalence of impaired quality of sleep in this population and to evaluate the pathophysiologic mechanisms linking MHT and impaired sleep quality.

In addition, our results suggest a close relationship between the non-dipper pattern, MHT, and impaired sleep quality. Erden *et al.* \[[@cit0017]\] found that poor sleep quality was related to a non-dipping pattern and acted as an independent predictor of non-dipping in newly diagnosed stage 1 hypertensive patients. Mansoor \[[@cit0018]\] used a logistic regression analysis to reveal that nighttime activity was predictive of a non-dipping BP profile and suggested a possible sleep disturbance in non-dipper hypertensive patients. Previous studies have clearly shown an association between a non-dipper pattern and increased cardiovascular disease risk in hypertensive patients \[[@cit0016], [@cit0019]\]. Additionally, previous studies have suggested that normotensive persons with a non-dipper pattern have increased target organ damage \[[@cit0020], [@cit0021]\]. The results of this study suggest that MHT patients with a non-dipper pattern and poor sleep quality should be closely monitored by clinicians.

Previous studies clearly showed that MHT predisposes to subclinical organ damage and to increased cardiovascular risk \[[@cit0022]--[@cit0025]\]. The MHT patients in our study had a significantly higher level of left ventricular hypertrophy (LVH) compared with the control group. Similarly, the Masked Hypertension Study by Shimbo *et al.* \[[@cit0022]\] showed that compared to healthy normotensive participants, left ventricular mass index (LVMI) was significantly higher in participants with MHT. Kotsis *et al.* \[[@cit0023]\] showed that MHT was accompanied by increased LVMI and carotid intima media thickness, even after adjusting for other risk factors. Interestingly, Mitsnefes *et al.* \[[@cit0024]\] suggested that LVH was more common in children with MHT. Also, in their multivariable analysis, MHT (OR = 4.1) was the strongest independent predictor of LVH in children. In addition, we found that left ventricular diastolic function was significantly impaired in MHT patients. Oe *et al.* \[[@cit0025]\] reported that left ventricular diastolic function was impaired in MHT compared with normotensive subjects independent of changes in left ventricular mass. Based on these results, we suggest that various subclinical organ damage and increased cardiovascular risk are observed in individuals with MHT. Clinicians should focus more on MHT patients for subclinical organ damage and increased cardiovascular risk.

Some limitations of this study should be discussed. The primary limitation of our study was the small sample size and selections of participants. A small sample size has low statistical power and thus may yield false-negative results. Also, PSQI scores are affected by many factors, but we tried to use some exclusion criteria to reduce that limitation. Accordingly, we cannot apply our results to the general population due to the broad exclusion criteria. Furthermore, the other limitation of our study is its cross-sectional design. Thus, our results cannot be extended to the general population. However, we believe that our findings provide a valuable contribution to the study of masked hypertension and sleep quality. Future prospective much larger multicenter studies are required to confirm our results.

In conclusion, this study demonstrates impaired sleep quality in subjects with MHT, particularly those with a non-dipper pattern. Additionally, this study indicates that impaired sleep quality may help diagnose MHT, particularly in the non-dipper group. Our findings will serve as the basis for future studies of the non-dipper BP pattern, sleep quality, and MHT. We should also emphasize that in this study, in contrast to previous reports, the subjects with MHT were evaluated in terms of sleep quality.
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